Compare KRUS & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRUS | TECX |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 650.6M | 549.5M |
| IPO Year | 2019 | N/A |
| Metric | KRUS | TECX |
|---|---|---|
| Price | $46.46 | $29.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $81.11 | $75.20 |
| AVG Volume (30 Days) | ★ 374.4K | 170.8K |
| Earning Date | 04-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,763,000.00 | N/A |
| Revenue This Year | $20.50 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.88 | N/A |
| 52 Week Low | $42.62 | $14.39 |
| 52 Week High | $95.98 | $35.99 |
| Indicator | KRUS | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 53.66 |
| Support Level | $42.81 | $27.31 |
| Resistance Level | $58.75 | $31.39 |
| Average True Range (ATR) | 2.98 | 1.97 |
| MACD | -0.49 | -0.01 |
| Stochastic Oscillator | 24.98 | 52.05 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.